Vermillion, Inc. (VRML): Price and Financial Metrics
GET POWR RATINGS... FREE!
VRML Stock Summary
- VRML's price/sales ratio is 78.61; that's higher than the P/S ratio of 97.25% of US stocks.
- Revenue growth over the past 12 months for Vermillion Inc comes in at 54.51%, a number that bests 90.62% of the US stocks we're tracking.
- In terms of volatility of its share price, VRML is more volatile than 98.55% of stocks we're observing.
- Stocks that are quantitatively similar to VRML, based on their financial statements, market capitalization, and price volatility, are JT, IMMR, INSP, AXGN, and ACRX.
- VRML's SEC filings can be seen here. And to visit Vermillion Inc's official web site, go to www.vermillion.com.
VRML Stock Price Chart Interactive Chart >
VRML Price/Volume Stats
|Current price||$4.00||52-week high||$5.78|
|Prev. close||$4.33||52-week low||$0.35|
|Day high||$4.25||Avg. volume||440,144|
|50-day MA||$2.14||Dividend yield||N/A|
|200-day MA||$1.07||Market Cap||389.51M|
VRML Latest News Stream
|Loading, please wait...|
VRML Latest Social Stream
View Full VRML Social Stream
Latest VRML News From Around the Web
Below are the latest news stories about Vermillion Inc that investors may wish to consider to help them evaluate VRML as an investment opportunity.
Vermillion (VRML) has changed its name to Aspira Women’s Health, effective today and will trade on the Nasdaq Stock Market under the new ticker symbol “AWH” and a new CUSIP (04537Y109), effective June 12. Valerie Palmieri, President, and Chief Executive Officer of Aspira Women’s Health said, “Our new company name...
Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on ovarian cancer risk assessment, today announced a major rebranding to reflect the company’s continuing evolution towards becoming a comprehensive gynecologic health company, including a corporate name change to Aspira Women’s Health Inc effective today, June 11, 2020. The company’s common stock will trade on the Nasdaq Stock Market under the new ticker symbol “AWH” effective June 12, 2020.
Vermillion (VRML) subsidiary ASPIRA Labs has finished validating Roche's Elecsys Anti-SARS-CoV-2 antibody blood test in addition to several new oncology biomarkers.The Roche assay demonstrated 100.0% sensitivity and 99.8% specificity.ASPIRA plans to offer the assay and additional pelvic mass risk assessment biomarkers by month-end in conjunction with its proprietary OVA1 plus...
Vermillion, Inc. (NASDAQ: VRML) shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including coronavirus antibody testings.The company is also expected to join the Russell 3000 Index on June 29.Vermillion is a diagnostic service and bio-analytic solutions provider company. It is engaged in the business of developing and commercializing diagnostic tests for the gynecologic disease. The company's products include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. Geographically all the operations are functioned from the region of U.S.Vermil...
Vermillion Completes Validation of New Pre-Surgical Test Offerings with OVA1®plus, including COVID-19 Antibody Testing and Additional Pelvic Mass Risk Assessment Biomarkers
AUSTIN, Texas, June 10, 2020 -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its.
VRML Price Returns